Marker Therapeutics
Pharmaceuticals, 4551 Kennedy Commerce Dr, Houston, Texas, 77032, United States, 11-50 Employees
Phone Number: 17*********
Who is MARKER THERAPEUTICS
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid t...
Read More
-
Headquarters: 4551 Kennedy Commerce Dr, Houston, Texas, 77032, United States
-
Date Founded: 2018
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from MARKER THERAPEUTICS
Marker Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Marker Therapeutics
Answer: Marker Therapeutics's headquarters are located at 4551 Kennedy Commerce Dr, Houston, Texas, 77032, United States
Answer: Marker Therapeutics's phone number is 17*********
Answer: Marker Therapeutics's official website is https://markertherapeutics.com
Answer: Marker Therapeutics's revenue is $25 Million to $50 Million
Answer: Marker Therapeutics's SIC: 2836
Answer: Marker Therapeutics's NAICS: 325414
Answer: Marker Therapeutics has 11-50 employees
Answer: Marker Therapeutics is in Pharmaceuticals
Answer: Marker Therapeutics contact info: Phone number: 17********* Website: https://markertherapeutics.com
Answer: We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Markers unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patients immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month